Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
16.38
+0.39 (2.44%)
Feb 21, 2025, 4:00 PM EST - Market closed
Syndax Pharmaceuticals Employees
Syndax Pharmaceuticals had 184 employees as of December 31, 2023. The number of employees increased by 77 or 71.96% compared to the previous year.
Employees
184
Change (1Y)
77
Growth (1Y)
71.96%
Revenue / Employee
$86,957
Profits / Employee
-$1,614,467
Market Cap
1.40B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
SNDX News
- 11 days ago - Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm - GlobeNewsWire
- 17 days ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 23 days ago - Syndax Announces Participation in February Investor Conferences - PRNewsWire
- 5 weeks ago - Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes - PRNewsWire
- 5 weeks ago - Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 6 weeks ago - Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 2 months ago - Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial - PRNewsWire
- 2 months ago - Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting - PRNewsWire